/
Cardiovascular
Acute Myocardial Infarction
37
Pipeline Programs↗
41
Active Trials↗
29
Companies Involved↗
Acute Myocardial Infarction is a moderately active landscape with 37 programs across 29 companies. The most active players are Novo Nordisk, Shanghai Hutchison Pharmaceuticals Limited, GSK. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical21
Phase 11
Phase 23
Phase 312
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
32 of 35 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.
Analysis
Trial Status
215
clinical trials
Completed129 · 60%
Unknown status29 · 13%
Recruiting20 · 9%
Not yet recruiting12 · 6%
Terminated9 · 4%
Active, not recruiting8 · 4%
Other8 · 4%
Clinical Trials
Trial Activity
215 trials
SUBDIMA Study: Subclinical Depression in Myocardial Infarction -Prevalence, Predictors and Prognostic Impact.
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Preclinical·NCT07492537·100 enrolled
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Recruiting·—·Phase 2·NCT05604131·89 enrolled
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
Recruiting·—·Phase 4·NCT05168462·776 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)